View Older Stories View More Recent Stories

Nov 12, 2018 06:13AM AstraZeneca (AZN) Reports Positive Full Results from DECLARE-TIMI 58 Cardiovascular Outcomes Trial for FARXIGA (dapagliflozin)
Nov 10, 2018 04:45PM FARXIGA Significantly Reduced Hospitalization for Heart Failure or CV Death in a Broad Patient Population with Type 2 Diabetes in the Landmark DECLARE-TIMI 58 Trial
Nov 1, 2018 07:00AM The Landmark DECLARE-TIMI 58 Cardiovascular Outcomes Trial of FARXIGA in Patients with Type 2 Diabetes to Be Featured at AHA 2018
Oct 22, 2018 07:00AM AstraZeneca to Present New Data Demonstrating Breadth of Research Portfolio in Renal Disease at ASN Kidney Week 2018
Oct 22, 2018 05:47AM AstraZeneca (AZN), Merck (MRK) Report Solo-1 Phase III Trial Demonstrates Lynparza Maintenance Therapy Cut the Risk of Disease Progression or Death by 70%
Oct 21, 2018 10:33AM Solo-1 Phase III Trial Demonstrates Lynparza Maintenance Therapy Cut the Risk of Disease Progression or Death by 70% in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer
Oct 16, 2018 06:32AM AstraZeneca (AZN) and Merck (MRK) Announce FDA Grants LYNPARZA Orphan Drug Designation for Pancreatic Cancer
Sep 25, 2018 08:23AM AstraZeneca (AZN) Says IMFINZI is First Immunotherapy to Demonstrate Significant OS Benefit in Unresectable, Stage III Lung Cancer
Sep 25, 2018 08:22AM IMFINZI® (durvalumab) is the First Immunotherapy to Demonstrate Significant Overall Survival Benefit in Unresectable, Stage III Lung Cancer
Sep 25, 2018 07:00AM AstraZeneca Ships FLUMIST® QUADRIVALENT Vaccine in the US for 2018-2019 Flu Season
Sep 24, 2018 07:02AM AstraZeneca (AZN) Says FARXIGA Achieved Positive Result in Phase III DECLARE-TIMI 58 Trial
Sep 24, 2018 07:00AM FARXIGA Achieved a Positive Result in the Phase III DECLARE-TIMI 58 Trial, a Large Cardiovascular Outcomes Trial in 17,000 Patients with Type 2 Diabetes
Sep 18, 2018 07:10AM AstraZeneca (AZN) Reports FASENRA (benralizumab) Shows Consistent Safety and Sustained Efficacy in Long-Term Phase III BORA Trial in Severe Eosinophilic Asthma
Sep 18, 2018 07:00AM FASENRA (benralizumab) Shows Consistent Safety and Sustained Efficacy in Long-Term Phase III BORA Trial in Severe Eosinophilic Asthma
Sep 18, 2018 07:00AM FASENRA (benralizumab) Shows Consistent Safety and Sustained Efficacy in Long-Term Phase III BORA Trial in Severe Eosinophilic Asthma
Sep 13, 2018 04:20PM AstraZeneca (AZN), MedImmune Report FDA Approval of LUMOXITI (moxetumomab pasudotox-tdfk) for Certain Patients with Relapsed or Refractory Hairy Cell Leukemia
Sep 13, 2018 04:14PM US FDA Approves LUMOXITI™ (moxetumomab pasudotox-tdfk) for Certain Patients with Relapsed or Refractory Hairy Cell Leukemia
Sep 7, 2018 02:00AM Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype
Aug 3, 2018 06:37AM AstraZeneca (AZN), Merck (MRK) Announce Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1
Jul 2, 2018 05:46AM UPDATE: Merck (MRK), AstraZeneca (AZN) Report Approval for LYNPARZA (olaparib) in Japan for BRCA-Mutated Metastatic Breast Cancer
Jun 27, 2018 07:11AM UPDATE: Merck (MRK), AstraZeneca (AZN) Report Positive Results from Phase 3 First-Line SOLO-1 Trial for Ovarian Cancer
Jun 27, 2018 07:00AM LYNPARZA® (olaparib) Significantly Delays Disease Progression in Phase III 1st-Line SOLO-1 Trial for Ovarian Cancer
Jun 25, 2018 08:10AM AstraZeneca (AZN) Says FARXIGA in Combination with ONGLYZA Demonstrates Similar Glycemic Control with Additional Benefits Vs. Insulin Glargine in Patients with Type 2 Diabetes
Jun 25, 2018 08:00AM FARXIGA in Combination with ONGLYZA Demonstrates Similar Glycemic Control with Additional Benefits Vs. Insulin Glargine in Patients with Type 2 Diabetes
Jun 19, 2018 07:00AM AstraZeneca to Share Latest Data from an Industry-Leading Portfolio That Aims to Advance Clinical Understanding of Diabetes and CV Risk Management at ADA 2018
Jun 12, 2018 06:15AM Lilly (LLY) and AstraZeneca (AZN) Halt Phase 3 Trials of Lanabecestat for Alzheimer's Disease Due to Futility
Jun 4, 2018 05:14PM LYNPARZA® (olaparib) in Combination With Abiraterone Delayed Disease Progression in Metastatic Castration-Resistant Prostate Cancer
Jun 4, 2018 05:03PM AstraZeneca (AZN), Merck (MRK) Report LYNPARZA in Combination with Abiraterone Delayed Disease Progression in mCRPC
Jun 4, 2018 06:00AM AstraZeneca (AZN) Udpates Moxetumomab Pasudotox Pivotal Data in Patients with Previously-Treated Hairy Cell LeukemiA
Jun 2, 2018 04:02PM Moxetumomab Pasudotox Pivotal Data in Patients with Previously-Treated Hairy Cell Leukemia Presented at the 2018 ASCO Meeting
May 25, 2018 07:01AM AstraZeneca (AZN) and MedImmune Announce IMFINZI Significantly Improves OS in Phase III Pacific Trial for Unresectable Stage III NSCLC
May 25, 2018 07:00AM IMFINZI® (Durvalumab) Significantly Improves Overall Survival in the Phase III Pacific Trial for Unresectable Stage III Non-Small Cell Lung Cancer
May 24, 2018 08:00AM AstraZeneca Heads to 2018 ASCO Annual Meeting with Its Diversified Oncology Portfolio and Next-Generation Pipeline
May 18, 2018 05:51PM LOKELMATM Approved in the US for the Treatment of Adults with Hyperkalemia
May 8, 2018 06:50AM AstraZeneca (AZN), Merck (MRK) LYNPARZA Tablets Receive EU Approval for Treatment of Platinum-Sensitive Relapsed Ovarian Cancer
Apr 16, 2018 05:58AM AstraZeneca (AZN) & Merck (MRK) Report Overall Survival Data for LYNPARZA (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer
Apr 15, 2018 04:50PM Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presented at AACR
Apr 3, 2018 08:04AM AstraZeneca (AZN) Reports FDA Approval of BYDUREON for use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control
Apr 3, 2018 08:00AM US FDA Approves BYDUREON for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control
Apr 3, 2018 07:03AM AstraZeneca (AZN) Granted FDA Approval for Biologics License Application for Moxetumomab Pasudotox in Hairy Cell Leukemia
Apr 3, 2018 07:00AM US FDA Accepts Biologics License Application for Moxetumomab Pasudotox in Hairy Cell Leukemia
Mar 19, 2018 12:16PM AstraZeneca (AZN) Presents New Data Evaluating Safety, Efficacy of FARXIGA
Mar 19, 2018 12:15PM AstraZeneca Presents New Data Evaluating Safety and Efficacy of FARXIGA in Patients with Type 2 Diabetes and Moderate Renal Impairment
Feb 21, 2018 03:08PM AstraZeneca (AZN) Reports Renewed Recommendation, Availability of FLUMIST QUADRIVALENT
Feb 21, 2018 03:07PM AstraZeneca Announces Renewed Recommendation and Availability of FLUMIST QUADRIVALENT Vaccine in the US
Feb 15, 2018 06:31AM AstraZeneca (AZN), Merck (MRK) Report Orphan Drug Designation by U.S. FDA for Neurofibromatosis Type 1
Jan 19, 2018 06:37AM Merck (MRK) and AstraZeneca (AZN) Granted Approval for LYNPARZA (Olaparib) in Japan
Jan 12, 2018 12:46PM AstraZeneca (AZN), Merck (MRK) Announce LYNPARZA Was Approved by US FDA in Germline BRCA-Mutated Metastatic Breast Cancer
Jan 12, 2018 12:45PM LYNPARZA® (olaparib) Approved by US FDA in Germline BRCA-Mutated Metastatic Breast Cancer
Dec 21, 2017 11:16AM AstraZeneca (AZN) Announces FDA Updated SYMBICORT Label with LABA Safety Class Revisions and Removed Boxed WARNING for Serious Asthma-Related Outcomes
View More Recent Stories View Older Stories